Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

NCT00193232 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Docetaxel
DRUG: Bortezomib

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]